Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria meets brain health: can a daily probiotic drink sharpen memory in older adults?

NCT ID NCT07818369

Symptom relief Sponsor: Anahuac University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether a daily synbiotic supplement can improve memory and thinking in adults aged 60 to 75 with mild cognitive impairment. The supplement combines Lactobacillus acidophilus LA-5 bacteria, agave inulin fiber, and almond powder. In this small crossover trial, participants receive either the synbiotic or a plain almond powder drink for 12 weeks, then switch to the other after a two-week break. The study measures changes in cognitive test scores and looks at gut bacteria, short-chain fatty acids, and markers of brain and immune function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a synbiotic supplement combining Lactobacillus acidophilus LA-5 probiotic bacteria and agave inulin fiber
What this could lead to
If it works, this could point toward a low-cost, food-based way to support memory and thinking in older adults with mild cognitive impairment.
What could go wrong
This is a small pilot study of 20 participants, so any cognitive changes may be modest or due to chance. Supplements can also cause digestive upset, and the trial may not show a clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 60 to 75 years. * Presence of mild cognitive impairment (MCI) determined by neuropsychological testing, meeting at least two of the following three established cutoff criteria: * Montreal Cognitive Assessment (MoCA): 19-26 points. * Memory Alteration Test (M@T): 28-37 points. * Mini-Mental State Examination (MMSE): 12-24 points. * Ability and willingness to provide written informed consent; consent may be provided by a family member or legal representative when necessary. Exclusion Criteria: * Previous diagnosis of severe cognitive impairment, Alzheimer disease, vascular dementia, or another neurodegenerative disorder affecting cognition. * History of cerebral ischemia, cerebrovascular events, traumatic brain injury, or advanced-stage renal disease. * Diagnosis of type 2 diabetes mellitus. * Diagnosed dysbiosis or inflammatory bowel disease, including ulcerative colitis or Crohn disease. * Use of antibiotics, laxatives, probiotics, or prebiotics within the 3 months prior to enrollment. * Habitual consumption of fermented foods or fiber-rich supplements, particularly fiber intake \>18 g/day. * Excessive alcohol consumption, defined as ≥2 alcoholic drinks per day, or history of alcohol dependence. * Chronic use of medications that may interfere with the microbiota-gut-brain axis, including immunosuppressants, antipsychotics, or corticosteroids. * Recent surgery within the previous 3 months or a planned medical intervention during the study period. * Known adverse reaction or hypersensitivity to any component of the synbiotic or to almond powder. * Uncontrolled chronic stress identified by clinical assessment. * Participation in intense physical activity or high-performance sports during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Unidad de Especialidades Médicas de la Defensa (UEMD)

    RECRUITING

    Mexico City, Mexico City, 11200, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.